Rapid detection of Ebolavirus using isothermal recombinase-aided amplification.
Ebolavirus
/ genetics
Hemorrhagic Fever, Ebola
/ diagnosis
Nucleic Acid Amplification Techniques
/ methods
Humans
Sensitivity and Specificity
Recombinases
/ metabolism
Molecular Diagnostic Techniques
/ methods
Africa, Western
/ epidemiology
Disease Outbreaks
RNA, Viral
/ genetics
DNA Primers
/ genetics
Ebolavirus
isothermal amplification
point‐of‐care
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
22
05
2024
received:
13
03
2024
accepted:
05
06
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
ppublish
Résumé
Ebolavirus disease (EVD) is an often-lethal disease caused by the genus Ebolavirus (EBOV). Although vaccines are being developed and recently used, outbreak control still relies on a combination of various factors, including rapid identification of EVD cases. This allows rapid patient isolation and control measure implementation. Ebolavirus diagnosis is performed in treatment centers or reference laboratories, which usually takes a few hours to days to confirm the outbreak or deliver a clear result. A fast and field-deployable molecular detection method, such as the isothermal amplification recombinase-aided amplification (RAA), could significantly reduce sample-to-result time. In this study, a RT-RAA assay was evaluated for EBOV detection. Various primer and probe combinations were screened; analytical sensitivity and cross-specificity were tested. A total of 40 archived samples from the 2014 to 2016 Ebola outbreak in West Africa were tested with both the reference method real-time RT-PCR and the established RT-RAA assay. The assay could detect down to 22.6 molecular copies per microliter. No other pathogens were detected with the Ebolavirus RT-RAA assay. Testing 40 samples yield clinical sensitivity and specificity of 100% each. This rapid isothermal RT-RAA assay can replace the previous RT-RPA and continue to offer rapid EBOV diagnostics.
Substances chimiques
Recombinases
0
RNA, Viral
0
DNA Primers
0
Types de publication
Journal Article
Evaluation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29744Subventions
Organisme : European and Developing Countries Clinical Trials Partnership (EDCTP)
Organisme : European Union
ID : RIA2018EF-2089 MobEBO-DRC
Informations de copyright
© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.
Références
Jacob ST, Crozier I, Fischer WA, et al. Ebola virus disease. Nat Rev Dis Primers. 2020;6:13.
Malenfant JH, Joyce A, Choi MJ, et al. Use of ebola vaccine: expansion of recommendations of the advisory committee on immunization practices to include two additional populations—United States, 2021. Morb Mortal Wkly Rep. 2022;71:290‐292.
WHO. Ebola Situation Report. WHO; 2015.
WHO. Ebola Virus Disease. WHO; 2021.
Mota DS, Guimarães JM, Gandarilla AMD, Filho JCBS, Brito WR, Mariúba LAM. Recombinase polymerase amplification in the molecular diagnosis of microbiological targets and its applications. Can J Microbiol. 2022;68:383‐402.
James A, Macdonald J. Recombinase polymerase amplification: emergence as a critical molecular technology for rapid, low‐resource diagnostics. Expert Rev Mol Diagn. 2015;15:1475‐1489.
Abd El Wahed A, El‐Deeb A, El‐Tholoth M, et al. A portable reverse transcription recombinase polymerase amplification assay for rapid detection of foot‐and‐mouth disease virus. PLoS One. 2013;8:e71642.
Munawar MA. Critical insight into recombinase polymerase amplification technology. Expert Rev Mol Diagn. 2022;22:725‐737.
Chen C, Li X, Li G, et al. Use of a rapid reverse‐transcription recombinase aided amplification assay for respiratory syncytial virus detection. Diagn Microbiol Infect Dis. 2018;90:90‐95.
Weidmann M, Mühlberger E, Hufert FT. Rapid detection protocol for filoviruses. J Clin Virol. 2004;30:94‐99.
Faye O, Faye O, Soropogui B, et al. Development and deployment of a rapid recombinase polymerase amplification Ebola virus detection assay in Guinea in 2015. Euro Surveill. 2015;20:30053.
RDC Team. A Language and Environment for Statistical Computing. 2009. http://www.R-project.org
Hadley W. Ggplot2: Elegant Graphics for Data Analysis. Springer; 2016.
Torreele E, Boum Y, Adjaho I, et al. Breakthrough treatments for Ebola virus disease, but no access—what went wrong, and how can we do better? Lancet. 2023;23(7):e253‐e258. doi:10.1016/S1473-3099(22)00810-6
World Health Organization. Therapeutics for Ebola Virus Disease. WHO; 2022
Team WER. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371:1481‐1495.
Kaushik A, Tiwari S, Dev Jayant R, Marty A, Nair M. Towards detection and diagnosis of Ebola virus disease at point‐of‐care. Biosens Bioelectr. 2016;75:254‐272.
Liu WB, Li ZX, Du Y, Cao GW. Ebola virus disease: from epidemiology to prophylaxis. Mil Med Res. 2015;2:7.
FIND. Target Product Profiles. https://www.finddx.org/tools-and-resources/rd-and-innovation/target-product-profiles/
WHO. Target Product Profile for Zaïre Ebolavirus Rapid, Simple Test to be Used in the Control of the Ebola Outbreak in West Africa. WHO; 2014.
WHO. WHO and FIND Formalize Strategic Collaboration to Drive Universal Access to Essential Diagnostics. WHO; 2020.
Dagens AB, Rojek A, Sigfrid L, Plüddemann A. The diagnostic accuracy of rapid diagnostic tests for Ebola virus disease: a systematic review. Clin Microbiol Infect. 2022;29:171‐181.
Wonderly B, Jones S, Gatton ML, et al. Comparative performance of four rapid Ebola antigen‐detection lateral flow immunoassays during the 2014‐2016 Ebola epidemic in West Africa. PLoS One. 2019;14:e0212113.
Budd J, Miller BS, Weckman NE, et al. Lateral flow test engineering and lessons learned from COVID‐19. Nat Rev Bioeng. 2023;1:13‐31.
Walker NF, Brown CS, Youkee D, et al. Evaluation of a point‐of‐care blood test for identification of Ebola virus disease at Ebola holding units, Western Area, Sierra Leone, January to February 2015. Euro Surveill. 2015;20:21073.
Chen H, Liu K, Li Z, Wang P. Point of care testing for infectious diseases. Clin Chim Acta. 2019;493:138‐147.
Lobato IM, O'Sullivan CK. Recombinase polymerase amplification: basics, applications and recent advances. Trends Anal Chem. 2018;98:19‐35.
Faye O, Diagne CT, Diallo A, et al. Molecular Diagnostics of Ebola Patient Samples by Institut Pasteur de Dakar Mobile Laboratory in Guinea 2014–2016: Emerging Challenges in Filovirus Infections. IntechOpen; 2019.
Euler M, Wang Y, Heidenreich D, et al. Development of a panel of recombinase polymerase amplification assays for detection of biothreat agents. J Clin Microbiol. 2013;51:1110‐1117.
Jani IV, Peter TF. Nucleic acid point‐of‐care testing to improve diagnostic preparedness. Clin Infect Dis. 2022;75:723‐728.
Kost GJ. Molecular and point‐of‐care diagnostics for Ebola and new threats: national POCT policy and guidelines will stop epidemics. Expert Rev Mol Diagn. 2018;18:657‐673.
Keita M, Lucaccioni H, Ilumbulumbu MK, et al. Evaluation of early warning, alert and response system for Ebola virus disease, Democratic Republic of the Congo, 2018–2020. Emerging Infect Dis. 2021;27:2988‐2998.